国际肿瘤学杂志

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (4): 267-270.doi: 10.3760/cma.j.issn.1673-422X.2016.04.007

• 论著 • 上一篇    下一篇

卵巢癌患者外周血清微小RNA-7表达及其临床意义 

焦丽敏,梁进,王琼,李纪强   

  1. 528200 广东省佛山市南海区第六人民医院妇科（焦丽敏、梁进、王琼）；南方医科大学珠江医院肿瘤中心（李纪强）
  • 出版日期:2016-04-08 发布日期:2016-03-02
  • 通讯作者: 李纪强，Email: banlangen12@126.com E-mail:banlangen12@126.com

Expression and clinical significance of microRNA7 in serum of ovarian cancer patients

Jiao Limin, Liang Jin, Wang Qiong, Li Jiqiang   

  1. Department of Gynecology, Sixth People′s Hospital of Foshan Nanhai District of Guangdong Province, Foshan 528200, China
  • Online:2016-04-08 Published:2016-03-02
  • Contact: Li Jiqiang E-mail:banlangen12@126.com

PDF

1028

摘要： 目的探讨微小RNA7（miR7）在卵巢癌患者血清中的表达及其临床意义。方法收集广东省佛山市南海区第六人民医院妇科2011年1月至2012年1月经病理组织学确诊的42例卵巢癌患者和40例在该院进行体检的健康女性的血清，采用反转录聚合酶链反应（RTPCR）分别检测两组血清样本miR7的表达，并分析其表达与卵巢癌临床特征的关系。结果与健康对照组相比，卵巢癌患者血清中miR7表达显著下降（0.246±0.017∶0.488±0.042），差异有统计学意义（t=11.23，P=0.01）。miR7的表达与患者临床分期（t=10.12，P=0.01）、组织学类型（t=6.90，P=0.02）、分化程度（t=4.46，P=0.03）、区域淋巴结或远处转移（t=5.62，P=0.02）有关，而与患者的年龄（t=0.03，P=0.83）无关。生存期分析结果显示，miR7高表达的卵巢癌患者总生存期长于低表达组（36.7个月∶24.3个月），差异有统计学意义（χ2=6.04，P=0.02）。结论miR7在卵巢癌患者血清中表达下调，有助于卵巢癌病情评估，可能是卵巢癌患者重要的预后指标之一。

关键词: 卵巢肿瘤, 微RNAs, 逆转录聚合酶链反应

Abstract: ObjectiveTo explore the expression and clinical significance of microRNA7 (miR7) in serum of ovarian cancer patients. MethodsSerum samples of 42 ovarian patients confirmed by pathological histology and 40 healthy women who underwent a physical exam were collected from January 2011 to January 2012 in the Sixth People′s Hospital of Foshan Nanhai District of Guangdong Province. Expression levels of miR7 in the serum samples of the two groups were examined using reverse transcriptionreal time polymerase chain reaction (RTPCR). The relationship between the expression of miR7 and the clinicopathologic feature of ovarian was analyzed. ResultsCompared with the controls, the expression of miR7 in the serum of ovarian cancer patients was significantly reduced (0.246±0.017 vs. 0.488±0.042), with a significant difference (t=11.23, P=0.01). The expression of miR7 in the serum of ovarian cancer patients was related to the clinical stage (t=10.12, P=0.01), pathological type (t=6.90, P=0.02), differentiation degree (t=4.46, P=0.03), regional lymph node or distant metastasis (t=5.62, P=0.02), but it was not related to the age (t=0.03, P=0.83). The patients with high miR7 expression had better overall survival than the patients with low miR7 expression (36.7 months vs. 24.3 months), with a significant difference (χ2=6.04, P=0.02). ConclusionThe expression of miR7 in serum of ovarian cancer patients is down regulated, which may be helpful for the overall assessment of ovarian carcinoma. miR7 may be one of the important prognostic indicators for ovarian carcinoma.

Key words: Ovarian neoplasms, MicroRNAs, Reverse transcriptase polymerase chain reaction